Capricor Therapeutics receives a STRONG SELL rating due to high regulatory risk surrounding its DMD therapy, Deramiocel. Hope-3 trial data reporting is confusing, with p-values for the primary ...
Based on prior, preclinical and clinical data, including 2 small randomized trials, I believe there is a high probability that Capricor Therapeutics' phase 3 trial will be positive. Topline results ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果